Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

3.17 (USD) • At close November 7, 2024
Bedrijfsnaam Acumen Pharmaceuticals, Inc.
Symbool ABOS
Munteenheid USD
Prijs 3.17
Beurswaarde 190,452,966
Dividendpercentage 0%
52-weken bereik 1.81 - 5.09
Industrie Biotechnology
Sector Healthcare
CEO Mr. Daniel J. O'Connell M.B.A.
Website https://acumenpharm.com

An error occurred while fetching data.

Over Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996

Vergelijkbare Aandelen

scPharmaceuticals Inc. logo

scPharmaceuticals Inc.

SCPH

4.32 USD

Spok Holdings, Inc. logo

Spok Holdings, Inc.

SPOK

16.76 USD

PDS Biotechnology Corporation logo

PDS Biotechnology Corporation

PDSB

3.28 USD

TFF Pharmaceuticals, Inc. logo

TFF Pharmaceuticals, Inc.

TFFP

1.63 USD

Sensus Healthcare, Inc. logo

Sensus Healthcare, Inc.

SRTS

6.54 USD

ProPhase Labs, Inc. logo

ProPhase Labs, Inc.

PRPH

1.43 USD

Allakos Inc. logo

Allakos Inc.

ALLK

1.35 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)